Inside the newly erected wet‑lab, scientists are already testing protocols that blend synthetic biology with AI‑generated designs. Two insiders, speaking on condition of anonymity, said the facility was built last week in a repurposed warehouse, a move that follows Anthropic's $400 million acquisition of Coefficient Bio to bolster its drug‑development toolkit.
Kauderer‑Abrams told Reuters that the lab will let Claude, Anthropic's flagship generative AI, guide robotic arms to pipette, plate, and read assays with minimal human intervention, but stressed that safety checks would still be overseen by skilled scientists. 'We are in the early innings of using AI to automate lab work,' he said, noting that the company will focus on preclinical projects in areas that traditional biotechs deem too risky or unprofitable.
The lab's launch comes as Anthropic grapples with heightened scrutiny over AI safety. Earlier this month, a team of researchers warned that the same technologies used to model protein folding could, if misapplied, accelerate biological weapons development. In response, Amodei has called for a deliberate slow‑down in AI deployment and is pushing the company toward a $2 trillion initial public offering to fund responsible research.
For Amodei, the drive is personal: his father died of a rare disease before a cure was found, prompting the CEO to write an essay on the therapeutic potential of AI. The lab will also host a cohort of scientists, including a former Novartis executive now on Anthropic's board, to help translate discoveries into treatments. The next milestone is the company's filing of its IPO prospectus in June, which will detail how the new biology arm will be leveraged to generate revenue.